Drug Profile
Research programme: diabetes therapy - Transition Therapeutics
Alternative Names: TT-402Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Transition Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Canada
- 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
- 24 Nov 2011 The programme is in active development